Loading data for CADL — first visit, this takes a few seconds.

Alert

Candel Therapeutics Inc. (CADL)

NasdaqGM: CADL · Real-Time Price · USD

13.07

-0.68 (-4.95%)

At close: Aug 28, 2026, 8:00 PM

13.07

+-0.00%

After-hours: 7:54 PM

The price, the headline numbers and the latest news, in one place.

-4.95% (1D)

No data available

Bid	7.49
Market Cap	1B
Revenue (ttm)	n/a
Net Income (ttm)	-88.53M
	-0.50
	-1.4
	n/a
	-20.91
P/B (ttm)	7.89
P/S (ttm)	n/a
Earnings Date	Nov 12, 2026

Ask	13.51
Volume	1,235,879
Avg. Volume (20D)	1,621,161
Open	13.70
Previous Close	13.75
Day's Range	12.93 - 13.80
52-Week Range	4.35 - 14.00
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About CADL

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develo...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 27, 2021

Employees 55

Stock Exchange NasdaqGM

Ticker Symbol CADL

Website https://www.candeltx.com

Full Company Profile

Financial Performance

In 2025, Candel Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -38.18M, a decrease of -30.8%.

Financial Statements

Earnings Surprise

Candel Therapeutics has released their quarterly earnings on Aug 13, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.36 misses estimates by -0.13, with -80.00% YoY decline.

Next Earnings Release

Candel Therapeutics Inc. is scheduled to release its earnings on Nov 12, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

1 week ago · Simply Wall St.

Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed?

Candel Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$38.91 million, up sharply from US$4.8 million a year earlier, with basic and diluted loss per share from continu...

1 week ago · Simply Wall St.

Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey

Candel Therapeutics (CADL) drew attention after reporting second quarter 2026 results that showed a net loss of US$38.91 million, compared with US$4.8 million a year earlier, indicating increased oper...

2 weeks ago · Stocktwits

CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4

If the FDA approves aglatimagene besadenovec in the treatment of certain patients with prostate cancer, it would mark the company’s first commercial product.

2 weeks ago · Stocktwits

CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity

Shares of Candel have drawn rising attention as the company advances its experimental immunotherapy, known as CAN-2409 or aglatimagene, toward potential approval in localized prostate cancer.

2 weeks ago · MarketBeat

Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up

Candel Therapeutics (NASDAQ:CADL) is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief S...

Page 1 of 2

Candel Therapeutics Inc. (CADL)